Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab

Smogorzewski, Jan; Sierro, Tiffany; Compoginis, Goli; Kim, Gene

doi:10.1016/j.jdcr.2018.11.007

Cited by 32 publications

(33 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our clinical practice, both appearance and healing of AA were observed during D treatment of AD. This conflicting experience is in agreement with what already reported in the literature (Alniemi & McGevna, 2019;Barroso-García et al, 2018;Darrigade et al, 2018;Dobkin et al, 2019;Flanagan et al, 2018;Kanda et al, 2019;Mitchell & Levitt, 2018;Penzi et al, 2018;Salgüero-Fernández et al, 2019;Sevray et al, 2019;Smogorzewski et al, 2019;Uchida et al, 2019).…”

Section: Discussionsupporting

confidence: 92%

“…All these subjects had been refractory to treatment for AA with topical steroids and systemic Cy, methotrexate, or prednisone. Hair regrowth occurred in all the patients on the scalp between 2 and 8 months after starting D (Alniemi & McGevna, ; Darrigade et al, ; Dobkin et al, ; Penzi et al, ; Sevray et al, ; Smogorzewski et al, ; Uchida et al, ). In two cases of AU, hair regrowth of eyebrow, axillary, and pubic hair growth was also observed (Darrigade et al, ; Smogorzewski et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…Hair regrowth occurred in all the patients on the scalp between 2 and 8 months after starting D (Alniemi & McGevna, ; Darrigade et al, ; Dobkin et al, ; Penzi et al, ; Sevray et al, ; Smogorzewski et al, ; Uchida et al, ). In two cases of AU, hair regrowth of eyebrow, axillary, and pubic hair growth was also observed (Darrigade et al, ; Smogorzewski et al, ). However, five cases of AA development after the beginning of D treatment were reported (Table ) (Barroso‐García et al, ; Flanagan et al, ; Kanda et al, ; Mitchell & Levitt, ; Salgüero‐Fernández et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…To date, remission or improvement of AA was reported in seven patients during treatment with D for AD and without the concomitant administration of other drugs for AA (Table 1) Sevray et al, 2019;Smogorzewski et al, 2019;Uchida et al, 2019). In particular, alopecia totalis was diagnosed in three cases, and alopecia universalis (AU) in the other four patients.…”

Section: Discussionmentioning

confidence: 99%

“…Due the AA persistence, D was stopped in one case only and reversal of hair loss was recorded after 8 weeks of therapy with topical triamcinolone acetonide 0.1% ointment on the scalp alternating weekly with tacrolimus 0.1% ointment and intralesional triamcinolone acetonide10 mg/mL(Flanagan et al, 2018).AD patients have up to 26-fold higher risk of developing AA than controls(Maloney et al, 2019). AA and AD share elevated IgE, filaggrin mutation, and some similar immune pathways including Th2 cytokines IL4 and IL13 upregulation(Andersen et al, 2017;Maloney et al, 2019;Smogorzewski et al, 2019). Because of the similar Th2 F I G U R E 1 Patient with concomitant atopic dermatitis and alopecia areata of scalp, eyebrows, and eyelashes (a) before and (b) after therapy with dupilumab cytokine profile between AA and AD, D might be useful also in AA, besides AD.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Dupilumab and alopecia: A Janus effect

Patruno

Napolitano

Ferrillo

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Atopic dermatitis (AD) and alopecia areata (AA) are two common skin diseases that can coexist in the same patient, sharing some pathogenetic mechanisms such as the overexpression of interleukin 4 (IL4) and interleukin 13 (IL13). Recently, cases of AA healing during treatment with anti‐IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported. However, cases of appearance of AA have been described during D treatment too. We report two patients that experienced these two opposite effects of D.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Dupilumab and alopecia: A Janus effect

Patruno

Napolitano

Ferrillo

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Kychygina

Cassagne

Tauber

et al. 2022

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre

Kreeshan

Al‐Janabi

Warren

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Dupilumab is a biologic therapy approved for treatment of moderate to severe atopic dermatitis (AD). Our objective was to assess the real-world effectiveness, safety and laboratory monitoring practices for dupilumab in a tertiary centre. Methods A retrospective review of medical records of all patients receiving dupilumab between September 2017 and October 2019 was undertaken. Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) were collected at weeks 0, 12–16 and 26–30. Data on laboratory tests undertaken for dupilumab screening and monitoring were also collected. Results At 12–16 weeks, 58.9% and 37.3% of patients achieved ≥ EASI 75 and ≥ EASI 90, respectively ( n = 156). Ninety-four patients underwent further analysis at weeks 26–30 with those achieving ≥ EASI 75 increasing from 61.7% (12–16 weeks) to 75.31%, and EASI 90 increasing from 35.8% (12–16 weeks) to 49.8%. The most common side effects were eye symptoms occurring in 43.1% of patients, with 16.3% developing conjunctivitis. The mean treatment duration was 255 days, during which an average of three sets of blood tests were performed ( n = 149). Of all laboratory abnormalities recorded, 24% started after initiation of dupilumab, and 93% were classified as ‘mild’. Dupilumab was not documented as causative in any of the cases, nor was treatment stopped on account of laboratory abnormalities. Conclusion Dupilumab provides an effective and safe treatment option for patients with AD. Clinical response continued to improve past 16 weeks in this real-world population. No laboratory abnormalities were felt to be secondary to dupilumab; screening and monitoring tests did not influence dupilumab prescribing. Electronic supplementary material The online version of this article (10.1007/s13555-020-00469-6) contains supplementary material, which is available to authorised users.

show abstract

Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab

Cited by 32 publications

References 10 publications

Dupilumab and alopecia: A Janus effect

Dupilumab and alopecia: A Janus effect

Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre

Contact Info

Product

Resources

About